Home › Companies › HALOZYME THERAPEUTICS INC. › 2024-2025
Compiled from SEC Form N-PX filings and HALOZYME THERAPEUTICS INC.’s Form 8-K, filed 2025-05-02 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Explore HALOZYME THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are HALOZYME THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-05-02 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Jeffrey W. Henderson | 98,993,463 | 3,298,117 | 95,045 | -- | 10,380,378 | Majority: yes |
| Elect Director: Helen I. Torley | 101,477,199 | 816,675 | 92,751 | -- | 10,380,378 | Majority: yes |
| Proposal 2: The advisory vote on the compensation of the Company's named executive officers was as follows: | 98,252,464 | 3,966,034 | 168,127 | -- | 10,380,378 | Passed |
| Proposal 3: The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 was as follows: | 112,028,211 | 659,976 | 78,816 | -- | -- | Passed |
Source: HALOZYME THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-05-02 — read the filing on EDGAR.
Each item below shows how the 514 asset managers that disclosed a HALOZYME THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 13 wordings of this item as funds reported it.
96% Passed · of votes cast
HALOZYME THERAPEUTICS INC.’s own tally for this item (“Proposal 2: The advisory vote on the compensation of the Company's named executive officers was as follows:”): 98,252,464 for, 3,966,034 against — passed, per its Form 8-K filed 2025-05-02 (Item 5.07). Of all 123,170,000 outstanding shares: 80% for, 3% against (83% of the company cast a for/against vote).
The 505 asset managers below cast 95% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 15,161,765 | 0 | 0 | 0 | For |
| BlackRock | 14,582,658 | 997 | 0 | 0 | For |
| State Street | 9,577,882 | 0 | 0 | 0 | For |
| Invesco | 0 | 4,304,786 | 0 | 0 | Against |
| AllianceBernstein | 3,767,001 | 0 | 0 | 0 | For |
| Charles Schwab | 3,538,887 | 0 | 0 | 0 | For |
| Fidelity | 3,525,129 | 0 | 0 | 0 | For |
| SNYDER CAPITAL MANAGEMENT L P | 3,463,937 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 3,093,192 | 0 | 0 | 0 | For |
| JPMorgan | 2,969,004 | 0 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 2,576,568 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,129,579 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,970,939 | 0 | 0 | 0 | For |
| Dimensional | 1,784,550 | 0 | 0 | 0 | For |
| Nuveen | 1,591,627 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 1,536,178 | 0 | 0 | 0 | For |
| CONGRESS ASSET MANAGEMENT CO | 1,527,346 | 0 | 0 | 0 | For |
| Capital Group | 1,496,896 | 0 | 0 | 0 | For |
| American Century | 1,478,025 | 0 | 0 | 0 | For |
| ArrowMark Colorado Holdings LLC | 1,466,043 | 0 | 0 | 0 | For |
| Putnam | 1,366,222 | 0 | 0 | 0 | For |
| Artisan | 1,319,998 | 0 | 0 | 0 | For |
| TIAA | 1,297,097 | 0 | 0 | 0 | For |
| Northern Trust | 1,197,910 | 0 | 0 | 0 | For |
| Stephens Investment Management Group LLC | 1,096,531 | 0 | 0 | 0 | For |
Showing the 25 largest of 505 asset managers. See all 505 in the interactive database.
Combines 4 wordings of this item as funds reported it.
99.2% Majority: yes · of votes cast
HALOZYME THERAPEUTICS INC.’s own tally for this item (“Elect Director: Helen I. Torley”): 101,477,199 for, 816,675 against, per its Form 8-K filed 2025-05-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 123,170,000 outstanding shares: 82% for, 0.7% against (83% of the company cast a for/against vote).
The 135 asset managers below cast 99.8% of the shares they voted on this item FOR (56,572,423 for, 62,375 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,665,245 | 0 | 0 | 0 | For |
| BlackRock | 9,674,728 | 0 | 0 | 0 | For |
| Fidelity | 3,221,194 | 0 | 0 | 0 | For |
| State Street | 3,087,240 | 0 | 0 | 0 | For |
| Invesco | 2,072,322 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,970,939 | 0 | 0 | 0 | For |
| Charles Schwab | 1,756,673 | 0 | 0 | 0 | For |
| Dimensional | 1,435,550 | 0 | 0 | 0 | For |
| TIAA | 1,297,097 | 0 | 0 | 0 | For |
| T. Rowe Price | 894,936 | 0 | 0 | 0 | For |
| JPMorgan | 870,773 | 0 | 0 | 0 | For |
| First Trust | 797,531 | 0 | 0 | 0 | For |
| Capital Group | 748,230 | 0 | 0 | 0 | For |
| Capitol Series Trust | 725,855 | 0 | 0 | 0 | For |
| American Century | 724,702 | 0 | 0 | 0 | For |
| AllianceBernstein | 705,155 | 0 | 0 | 0 | For |
| Putnam | 653,905 | 0 | 0 | 0 | For |
| Equitable | 637,751 | 0 | 0 | 0 | For |
| Artisan | 468,338 | 0 | 0 | 0 | For |
| PROFESSIONALLY MANAGED PORTFOLIOS | 456,742 | 0 | 0 | 0 | For |
| Victory Capital | 422,252 | 0 | 0 | 0 | For |
| Jackson National | 403,486 | 0 | 0 | 0 | For |
| GLENMEDE FUND INC | 386,531 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 378,160 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 359,876 | 0 | 0 | 0 | For |
Showing the 25 largest of 135 asset managers. See all 135 in the interactive database.
Combines 4 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
HALOZYME THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jeffrey W. Henderson”): 98,993,463 for, 3,298,117 against, per its Form 8-K filed 2025-05-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 123,170,000 outstanding shares: 80% for, 3% against (83% of the company cast a for/against vote).
The 135 asset managers below cast 98% of the shares they voted on this item FOR (55,284,287 for, 1,236,011 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,665,245 | 0 | 0 | 0 | For |
| BlackRock | 9,674,728 | 0 | 0 | 0 | For |
| Fidelity | 3,221,194 | 0 | 0 | 0 | For |
| State Street | 3,087,240 | 0 | 0 | 0 | For |
| Invesco | 2,072,322 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,970,939 | 0 | 0 | 0 | For |
| Charles Schwab | 1,756,673 | 0 | 0 | 0 | For |
| Dimensional | 1,435,550 | 0 | 0 | 0 | For |
| TIAA | 1,297,097 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 894,936 | 0 | 0 | Against |
| JPMorgan | 870,773 | 0 | 0 | 0 | For |
| First Trust | 797,531 | 0 | 0 | 0 | For |
| Capital Group | 748,230 | 0 | 0 | 0 | For |
| Capitol Series Trust | 725,855 | 0 | 0 | 0 | For |
| American Century | 724,702 | 0 | 0 | 0 | For |
| AllianceBernstein | 705,155 | 0 | 0 | 0 | For |
| Putnam | 653,905 | 0 | 0 | 0 | For |
| Equitable | 637,751 | 0 | 0 | 0 | For |
| Artisan | 468,338 | 0 | 0 | 0 | For |
| PROFESSIONALLY MANAGED PORTFOLIOS | 456,742 | 0 | 0 | 0 | For |
| Victory Capital | 422,252 | 0 | 0 | 0 | For |
| Jackson National | 403,486 | 0 | 0 | 0 | For |
| GLENMEDE FUND INC | 386,531 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 378,160 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 359,876 | 0 | 0 | 0 | For |
Showing the 25 largest of 135 asset managers. See all 135 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.4% Passed · of votes cast
HALOZYME THERAPEUTICS INC.’s own tally for this item (“Proposal 3: The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 was as follows:”): 112,028,211 for, 659,976 against — passed, per its Form 8-K filed 2025-05-02 (Item 5.07). Of all 123,170,000 outstanding shares: 91% for, 0.6% against (91% of the company cast a for/against vote).
The 135 asset managers below cast 99.9% of the shares they voted on this item FOR (56,633,066 for, 724 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,665,245 | 0 | 0 | 0 | For |
| BlackRock | 9,674,728 | 0 | 0 | 0 | For |
| Fidelity | 3,221,194 | 0 | 0 | 0 | For |
| State Street | 3,087,102 | 138 | 0 | 0 | For |
| Invesco | 2,072,322 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,970,939 | 0 | 0 | 0 | For |
| Charles Schwab | 1,756,673 | 0 | 0 | 0 | For |
| Dimensional | 1,435,550 | 0 | 0 | 0 | For |
| TIAA | 1,297,097 | 0 | 0 | 0 | For |
| T. Rowe Price | 894,936 | 0 | 0 | 0 | For |
| JPMorgan | 870,773 | 0 | 0 | 0 | For |
| First Trust | 797,531 | 0 | 0 | 0 | For |
| Capital Group | 748,230 | 0 | 0 | 0 | For |
| Capitol Series Trust | 725,855 | 0 | 0 | 0 | For |
| American Century | 724,702 | 0 | 0 | 0 | For |
| AllianceBernstein | 705,155 | 0 | 0 | 0 | For |
| Putnam | 653,905 | 0 | 0 | 0 | For |
| Equitable | 637,751 | 0 | 0 | 0 | For |
| Artisan | 468,338 | 0 | 0 | 0 | For |
| PROFESSIONALLY MANAGED PORTFOLIOS | 456,742 | 0 | 0 | 0 | For |
| Victory Capital | 422,252 | 0 | 0 | 0 | For |
| Jackson National | 403,486 | 0 | 0 | 0 | For |
| GLENMEDE FUND INC | 386,531 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 378,160 | 0 | 0 | 0 | For |
| BOSTON TRUST WALDEN FUNDS | 359,876 | 0 | 0 | 0 | For |
Showing the 25 largest of 135 asset managers. See all 135 in the interactive database.
Ranked by the number of HALOZYME THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 123,170,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 12.31% |
| 2 | BlackRock | 11.84% |
| 3 | State Street | 7.78% |
| 4 | Invesco | 3.49% |
| 5 | AllianceBernstein | 3.06% |
| 6 | Charles Schwab | 2.88% |
| 7 | Fidelity | 2.86% |
| 8 | SNYDER CAPITAL MANAGEMENT L P | 2.81% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 2.51% |
| 10 | JPMorgan | 2.41% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 13.88% | 13F |
| Vanguard Group | 10.42% | 13F |
| STATE STREET CORPORATION | 4.91% | 13G |
| Invesco | 3.16% | 13F |
| Helen I. Torley | 2.03% | DEF14A |
| JPMorgan Chase | 2.01% | 13F |
| Dimensional Fund Advisors | 1.65% | 13F |
| Morgan Stanley | 1.57% | 13F |
| Charles Schwab | 1.42% | 13F |
| Northern Trust | 1.41% | 13F |
Percentages above are of 123,170,000 shares outstanding, as reported by HALOZYME THERAPEUTICS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from HALOZYME THERAPEUTICS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At HALOZYME THERAPEUTICS INC.'s shareholder meeting held 2025-05-01, in the 2024-2025 proxy season, 514 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 2,616 separate fund positions. On the most widely held item on that ballot — To approve, by a non-binding advisory vote, the compensation of the Company's named executive… — the proposal passed with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: HALOZYME THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-05-02.
HALOZYME THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.